Teleflex (TFX) 주식 개요
미국, 유럽, 중동, 아프리카, 아시아 태평양 및 국제적으로 중환자 치료 및 수술 분야에서 일반적인 진단 및 치료 절차를 위한 일회용 의료 기기를 설계, 개발, 제조 및 공급하는 Teleflex Incorporated. 자세히 보기
TFX Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Teleflex Incorporated 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$131.90 |
| 52주 최고가 | US$139.67 |
| 52주 최저가 | US$100.18 |
| 베타 | 0.81 |
| 1개월 변동 | 5.73% |
| 3개월 변동 | 14.25% |
| 1년 변동 | 9.06% |
| 3년 변동 | -43.43% |
| 5년 변동 | -67.25% |
| IPO 이후 변동 | 35,107.88% |
최근 뉴스 및 업데이트
Recent updates
내러티브 업데이트 • May 02
TFX: Business Separation And Portfolio Focus Will Reshape Future Earnings Profile
Analysts have reduced their fair value estimate for Teleflex to $147 from $155, citing updated assumptions for revenue growth, profit margins, and future P/E multiples following recent upgrades and price target increases from several research firms. Analyst Commentary Recent research has skewed more optimistic on Teleflex, with several bullish analysts updating their views following the company’s Q4 results, guidance, and plans for a major business transformation.
내러티브 업데이트 • Apr 17
TFX: Business Separation Execution And Activist Pressure Will Constrain Forward Upside
Teleflex's analyst price target is now framed slightly higher, moving from about $115 to roughly $117. Analysts are factoring in updated assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E following recent upgrades and price target increases tied to the company's ongoing business separation and portfolio optimization efforts.내러티브 업데이트 • Apr 03
TFX: Business Separation And Activist Pressure Will Shape Balanced Forward Outlook
Analysts have raised their average price target for Teleflex to $125 from $115. They cite the company’s ongoing business separation, portfolio optimization, and preparation for future value-creating opportunities as key reasons for the change.내러티브 업데이트 • Mar 20
TFX: Business Separation And Leadership Changes Will Shape Balanced Forward Outlook
Narrative update Analysts have raised the Teleflex price target by $10, to $125 from $115, citing the company's business separation efforts, portfolio optimization, and positioning for future value creating opportunities following recent results and guidance. Analyst Commentary Recent research highlights a mixed backdrop for Teleflex, with some firms adjusting targets higher while others stay guarded.내러티브 업데이트 • Mar 06
TFX: Business Separation And Portfolio Optimization Will Drive Future Earnings Quality
Narrative Update on Teleflex The analyst price target on Teleflex has shifted toward $125, with analysts pointing to the company’s ongoing business separation, portfolio optimization, and positioning for future value-creating opportunities as key factors behind the revised outlook. Analyst Commentary Bullish analysts are pointing to recent price target moves and rating actions as signals of growing confidence in Teleflex’s ability to execute on its transformation plan and to support higher valuation levels over time.
내러티브 업데이트 • Feb 20
TFX: Higher Margin Assumptions And CEO Transition Will Shape Bullish Outlook
Narrative Update on Teleflex The updated analyst price target on Teleflex has shifted by $23, with analysts citing refreshed views on long term profit margins and a slightly higher assumed future P/E multiple as key drivers behind the change. Analyst Commentary Recent Street research on Teleflex reflects a mix of optimism about the company’s long term potential and caution around valuation and execution, which helps explain the updated price target.내러티브 업데이트 • Feb 06
TFX: CEO Transition And Refined Assumptions Will Shape Bullish Future Outlook
Analysts have adjusted their price targets on Teleflex by aligning fair value estimates to about $129.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions highlighted in recent research, including a Wells Fargo target cut and a Needham upgrade.내러티브 업데이트 • Jan 23
TFX: Leadership Transition And Softer Demand Will Shape Steady Forward Outlook
Analysts kept their Teleflex fair value estimate steady at US$115.00, as slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E led them to view the prior price target as still appropriate. What's in the News Board member Stuart Randle has been appointed Interim President and CEO effective January 8, 2026, replacing Liam Kelly.내러티브 업데이트 • Jan 09
TFX: Softer Demand And Leadership Change Will Shape Balanced Outlook
Analysts have reduced their price target on Teleflex from US$120.00 to US$115.00, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News Teleflex issued preliminary 2025 revenue guidance of US$3.270b to US$3.278b, below its prior outlook of US$3.305b to US$3.320b, citing softer demand for intra aortic balloon pumps and catheters in the U.S. and Asia, delays in OEM purchase orders, and lower order volumes across parts of its portfolio (Key Developments).내러티브 업데이트 • Dec 20
TFX: Margin Expansion Will Drive Stronger Earnings Despite Revenue Headwinds
Analysts have raised their price target on Teleflex from 152.80 dollars to 155.00 dollars, reflecting expectations for meaningfully higher profit margins that more than offset slightly slower projected revenue growth and a lower future earnings multiple. What's in the News Teleflex narrowed its full year 2025 GAAP revenue growth outlook to 9.10% to 9.60%, and now expects revenue between 3,325 million dollars and 3,340 million dollars.Seeking Alpha • Dec 10
Teleflex: Selling, But How Much?
Summary Teleflex Incorporated rebounded from lows after announcing a $2.03B divestiture of Acute Care, Interventional Urology, and OEM businesses. TFX will use $1B of net proceeds for share buybacks, reducing pro forma net debt to $1.5B, but revenue impact remains ambiguous. Shares now trade at 10x adjusted earnings, with market reaction positive despite uncertainty around divested revenue figures. I maintain a cautious long position, closely monitoring Q4 results to clarify divestment implications and future margin trajectory. Read the full article on Seeking Alpha내러티브 업데이트 • Dec 06
TFX: Diabetes Trial And Goodwill Charge Will Shape Balanced Future Outlook
Analysts have modestly adjusted their price target on Teleflex, keeping fair value steady at approximately $124.14 per share while refining assumptions for a slightly lower discount rate and marginally improved long term valuation metrics. This reflects incremental confidence in the company’s earnings durability.내러티브 업데이트 • Nov 22
TFX: Future Diabetes Trial Progress Will Drive Upside Despite Margin Pressures
Teleflex's analyst price target has been revised downward by $3.57 to $124.14. Analysts cite modest reductions in expected profit margins and growth as driving factors for the update.분석 기사 • Nov 09
Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34
Teleflex Incorporated ( NYSE:TFX ) has announced that it will pay a dividend of $0.34 per share on the 15th of...내러티브 업데이트 • Nov 07
TFX: Future Advances In Diabetes Trials And Asian Market Expansion Will Drive Upside
Analysts have revised their price target for Teleflex downward from $132.63 to $127.71. They cite higher discount rates and softer revenue growth projections, despite improved profit margins and a lower expected future price-to-earnings ratio.분석 기사 • Oct 30
Teleflex Incorporated (NYSE:TFX) Not Lagging Market On Growth Or Pricing
Teleflex Incorporated's ( NYSE:TFX ) price-to-earnings (or "P/E") ratio of 29.5x might make it look like a strong sell...분석 기사 • Sep 11
These 4 Measures Indicate That Teleflex (NYSE:TFX) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...내러티브 업데이트 • Aug 29
Acquisitions And Asian Expansion Will Broaden Healthcare Horizons
Despite a near-term upside from strong Q2 results, Teleflex’s consensus price target has been revised down to $132.62 due to persistently modest organic growth and muted EPS increases, with valuation already reflecting current expectations despite anticipated second-half acceleration. Analyst Commentary Strong Q2 results provided near-term upside surprise.분석 기사 • Aug 04
Results: Teleflex Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates
Last week saw the newest quarterly earnings release from Teleflex Incorporated ( NYSE:TFX ), an important milestone in...분석 기사 • Aug 03
Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34
Teleflex Incorporated ( NYSE:TFX ) has announced that it will pay a dividend of $0.34 per share on the 15th of...분석 기사 • Jul 10
Teleflex Incorporated (NYSE:TFX) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 35.1x Teleflex Incorporated ( NYSE:TFX ) may be sending very bearish...분석 기사 • Jun 22
Investors Met With Slowing Returns on Capital At Teleflex (NYSE:TFX)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...Seeking Alpha • Mar 02
Teleflex's Bold Transformation: Why I'm Skeptical On Value Creation
Summary Teleflex's management announced a significant acquisition and business split, but the market reacted negatively, dropping the shares over 20%. Fourth quarter earnings and 2025 guidance show weak revenue growth and margin leverage, with potential risks from tariffs and poor execution in key areas. The acquisition of BIOTRONIK's vascular intervention business is risky; it expands Teleflex's vascular intervention business, but the end markets aren't growing that fast and the company is a smaller player. Splitting the business into RemainCo and NewCo makes strategic sense, but NewCo may struggle with growth and margin leverage as a smaller entity. Even with conservative modeling and valuation assumptions, Teleflex stock looks undervalued by more than 20%, but it's tough to recommend a stock where I have serious doubts about execution and strategy. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
Teleflex Incorporated: Compelling Only On One Metric
Summary Teleflex Incorporated, a diversified medical device company, saw a 17% stock drop after Q3 results in late October. The stock now trades at under 13.5 EPS (non-GAAP) and at the equity's lowest price-to-sales ratio in a decade. Have the shares fallen into the 'buy zone'? An analysis of Teleflex Incorporated follows in the paragraphs below. Read the full article on Seeking Alpha주주 수익률
| TFX | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | 1.2% | 3.0% | -0.8% |
| 1Y | 9.1% | -18.3% | 27.1% |
수익률 대 산업: TFX은 지난 1년 동안 -18.3%의 수익을 기록한 US Medical Equipment 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: TFX은 지난 1년 동안 27.1%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| TFX volatility | |
|---|---|
| TFX Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: TFX는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: TFX의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1943 | 15,500 | Stu Randle | www.teleflex.com |
Teleflex Incorporated는 미국, 유럽, 중동, 아프리카, 아시아 태평양 및 국제적으로 중환자 치료 및 수술 분야에서 일반적인 진단 및 치료 절차를 위한 일회용 의료 기기를 설계, 개발, 제조 및 공급합니다. 이 회사는 정맥 내 치료, 혈압 측정, 혈액 샘플 채취를 위한 Arrow 브랜드 카테터, 카테터 내비게이션 및 팁 포지셔닝 시스템, 골내 접근 시스템으로 구성된 혈관 및 응급 의학 제품, EZ-IO 골내 혈관 접근 시스템, Arrow FAST1 흉골 내 주입 시스템으로 구성된 골내 접근 시스템, QuikClot 브랜드의 외상 제품 등 지혈 제품 등을 제공합니다. 또한 다양한 관상동맥 카테터, 구조적 심장 지지 장치 및 말초 중재 제품 플랫폼, 가이드라이너, 턴파이크, 트랩라이너 카테터, 만타 혈관 폐쇄 장치 및 애로우 온컨트롤 전동 골 생검 시스템, 약물 코팅 풍선, 스텐트, 풍선 카테터 등 관상동맥 및 주변 의료 기기를 포함한 인터벤션 제품도 제공합니다.
Teleflex Incorporated 기초 지표 요약
| TFX 기초 통계 | |
|---|---|
| 시가총액 | US$5.98b |
| 순이익 (TTM) | US$1.36m |
| 매출 (TTM) | US$2.13b |
4,300x
주가수익비율(P/E)2.7x
주가매출비율(P/S)TFX는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| TFX 손익계산서 (TTM) | |
|---|---|
| 매출 | US$2.13b |
| 매출원가 | US$949.97m |
| 총이익 | US$1.18b |
| 기타 비용 | US$1.18b |
| 순이익 | US$1.36m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 0.031 |
| 총이익률 | 55.33% |
| 순이익률 | 0.064% |
| 부채/자본 비율 | 86.6% |
TFX의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| Teleflex 배당 일정 | |
|---|---|
| 배당락일 | May 22 2026 |
| 배당 지급일 | Jun 30 2026 |
| 배당락일까지 남은 일수 | 0 days |
| 배당 지급일까지 남은 일수 | 39 days |
TFX는 안정적으로 배당을 지급합니까?
TFX 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 08:22 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Teleflex Incorporated는 26명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Matthew Taylor | Barclays |
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |